PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | $1.50M | $1.18M | N/A | N/A | N/A | $106.00K |
| Gross Profit | $-1.50M | $-1.18M | N/A | N/A | N/A | $-106.00K |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Expenses | $96.23M | $83.58M | $68.30M | $27.11M | $1.88M | $1.25M |
| Operating Income | $-97.74M | $-84.77M | $-68.30M | $-27.11M | $-1.88M | $-1.35M |
| Operating Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income | $-89.98M | $-78.63M | $-69.10M | $-27.28M | $-1.89M | $-1.35M |
| Net Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS (Basic) | $-2.85 | $-3.30 | $-4.42 | $-1.22 | $-0.53 | $-0.06 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A |